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normal	 diameter.	 The	 normal	 diameter	 of	 the	 infrarenal	 aorta	 is	 approximately	 20mm,	
therefore	an	aortic	diameter	of	30mm	or	larger	is	considered	being	aneurysmatic.	AAAs	are	
a	 significant	 health	 challenge	 with	 an	 estimated	 incidence	 of	 20	 –	 40	 cases	 per	 100,000	
population	per	year.		Its	more	commonly	seen	in	men	than	in	women,	with	a	prevalence	of	
1.3%	 to	 8.9%	 in	 males	 and	 1.0%	 tot	 2.2%	 in	 females.	 The	 prevalence	 of	 AAA	 in	 The	
Netherlands	 is	 approximately	90.000	among	people	older	 than	55	years	of	age.	 Important	
risk	factors	for	the	occurrence	of	AAA	are	gender,	age	and	smoking	habits.	
	
An	AAA	 is	a	progressive	disease,	which	 if	 left	untreated	eventually	 leads	 to	 rupture	of	 the	
aneurysm	with	massive	bleeding	and	consequently	death.	To	date,	AAAs	are	responsible	for	




The	 risk	 of	 rupture	 increases	 with	 the	 aneurysm	 diameter.	 Initial	 treatment	 of	 an	 AAA	 is	




becomes	 symptomatic	 (abdominal	 or	 back	 pain).	 AAAs	 are	 responsible	 for	 approximately	
7.000	hospital	admissions	yearly	in	The	Netherlands.		
	
Two	 modalities	 of	 AAA	 treatment	 are	 available;	 conventional	 open	 surgical	 repair	 or	
minimally	 invasive	 endovascular	 repair	 (EVAR).	 In	 open	 repair	 the	 aneurysmatic	 aorta	 is	
replaced	by	a	synthetic	graft.	This	treatment	requires	laparotomy,	clamping	of	the	aorta	and	




stentgraft	 is	 fed	 from	 femoral	 artery	 access	 in	 the	 groin	 through	 the	aorta	up	 to	 the	AAA	
neck	and	subsequently	unfolded,	excluding	the	aneurysm	sac	from	blood	flow	and	pressure.	
Initially,	 EVAR	was	 considered	 to	 be	 an	 alternative	 treatment	 for	 those	 AAA	 patients	 not	
suitable	 for	 open	 repair	 due	 to	 severe	morbidities.	Meanwhile,	 EVAR	 has	 proven	 to	 be	 a	
feasible	and	safe	technique,	showing	decreased	mortality	and	morbidity	rates	compared	to	





a	 substantial	 proportion	 (40%)	 of	 AAA	 patients	 that	 require	 repair	 fall	 outside	 stringent	
anatomic	 criteria	 that	 make	 treatment	 with	 commercially	 available	 stentgrafts	 suitable.		
Improvement	 of	 EVAR	 treatment	 is	 necessary	 to	 enhance	 outcomes	 of	 AAA	 patients.	 The	
technology	 of	 EVAR	 is	 a	 dynamic	 ever-changing	 endeavour.	 The	 challenge	 is	 to	 decrease	
complications	and	reinterventions,	while	safely	 treating	more	complex	anatomy,	especially	
those	cases	unfit	for	open	repair.	In	the	mean	time	hold	dear	to	resource-effective	strategies	
that	 do	 not	 include	 technically	 complex	 and	 costly	 interventions	 when	 they	 are	 not	
necessary.	 Both	 patients	 and	 society	 as	 a	 whole	 benefit	 from	 simply	 applicable	 and	












contemporary	 EVAR	 devices	 and	 put	 these	 results	 in	 perspective	 to	 older	 generations	 of	
devices	en	conventional	open	surgical	AAA	treatment.	Chapter	2	describes	the	performance	
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year	 results	 are	promising.	 Complication	 and	 reintervention	 rates	 compare	beneficial	with	







consensus	 on	 which	 type	 of	 anaesthesia	 is	 most	 suitable.	 Chapter	 4	 strengthens	 the	








is	 really	necessary	or	 if	 iliac	 stenting	with	 the	omission	of	 coil	 embolisation	 is	 also	 safe	 to	
perform.	 A	 review	 of	 literature	 in	 Chapter	 5	 shows	 that	 so-feared	 IIA-related	 endoleaks	
following	 IIA	 stentgraft	 coverage	 without	 prior	 coil	 embolisation	 are	 rarely	 reported.	
Suggested	pre-emptive	coil	embolisation	as	a	preventative	measure	related-endoleaks	may	
therefore	be	unnecessary.	Furthermore,	results	 from	a	strategy	 in	which	stent	coverage	of	
the	 IIA	was	 routinely	performed	without	prior	 coil	 embolisation	 show	 that	 this	 strategy	 in	
EVAR	 treatment	 of	 aorto-iliac	 and	 iliac	 aneurysms	 is	 safe	 and	 effective,	 and	 may	 reduce	










and	 treatment	 options	 of	 all	 types	 of	 endoleaks,	 device	 migration,	 stent	 fractures,	 graft	
detoriation,	 or	 even	 persistent	 aneurysm	 growth	 that	 EVAR	 patients	 may	 experience.	
Advanced	 stent	 graft	 designs	 and	 increased	 understanding	 of	 management	 of	 these	
technical	 complications	 are	 declining	 the	 incidence	 rate	 for	 the	 necessity	 of	 secondary	
interventions,	which	is	considered	the	down-side	of	EVAR	and	matter	of	great	concern	in	the	






Randomized	 controlled	 trials	 (RCTs)	 are	 considered	 the	 gold	 standard	 in	 the	 hierarchy	 of	
research	designs	for	evaluating	the	efficacy	and	safety	of	a	treatment	 intervention.	Results	
of	 RCTs,	 however,	 may	 not	 reflect	 ‘real	 world’	 since	 patient	 inclusion	 is	 subject	 to	 strict	
criteria,	and	can	therefore	have	limited	applicability	to	individual	patients	in	clinical	setting.	
Moreover,	one	must	question	if	RCT	design	is	feasible	in	qualifying	outcome	of	EVAR	in	view	
of	 the	 contemporary	 preference	 for	 EVAR	 and	 the	 swift	 evolution	 in	 stent	 graft	 designs.	
Large	high-quality,	well-designed	observational	studies	are	 increasingly	believed	to	provide	
complementary	 evidence	 to	 RCTs.	 They	 can	 assess	 treatment	 effectiveness	 in	 patients	
encountered	 in	 day-to-day	 clinical	 practice	 because	 of	 the	 use	 of	 larger	 and	 more	
heterogeneous	 populations	 with	 common	 comorbidities	 and	 longer	 follow-up	 periods.	 A	
mandatory	registry	on	AAA-treatment	that	is	globally	supported	by	doctors	and	is	financially	




development	 of	 national	 and	 international	 guidelines	 that	 give	 guidance	 to	 the	 optimal	
treatment	of	abdominal	 aortic	 aneurysms.	Above	all	making	AAA	disease	a	 less	 lethal	 and	
more	bearable	disease.	
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